PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
30.49%
Revenue growth 1.25-1.5x ENPH's 20.86%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
15.26%
Gross profit growth at 50-75% of ENPH's 21.20%. Martin Whitman would question if cost structure or brand is lagging.
231.50%
EBIT growth 1.25-1.5x ENPH's 176.09%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
233.84%
Operating income growth 1.25-1.5x ENPH's 176.09%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
127.15%
Net income growth comparable to ENPH's 126.82%. Walter Schloss might see both following similar market or cost trajectories.
118.18%
EPS growth similar to ENPH's 128.13%. Walter Schloss would assume both have parallel share structures and profit trends.
122.22%
Similar diluted EPS growth to ENPH's 128.13%. Walter Schloss might see standard sector or cyclical influences on both firms.
1.12%
Share count expansion well above ENPH's 1.13%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.90%
Diluted share reduction more than 1.5x ENPH's 14.39%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
75.45%
OCF growth under 50% of ENPH's 7724.49%. Michael Burry might suspect questionable revenue recognition or rising costs.
52.35%
FCF growth under 50% of ENPH's 347.18%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
2.55%
Positive 5Y CAGR while ENPH is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
-29.64%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
No Data
No Data available this quarter, please select a different quarter.
-129.65%
Negative 5Y OCF/share CAGR while ENPH is at 110.64%. Joel Greenblatt would question the firm’s operational model or cost structure.
-212.65%
Negative 3Y OCF/share CAGR while ENPH stands at 105.56%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
No Data
No Data available this quarter, please select a different quarter.
18.49%
Below 50% of ENPH's 100.46%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
106.47%
3Y net income/share CAGR similar to ENPH's 100.39%. Walter Schloss would attribute it to shared growth factors or demand patterns.
No Data
No Data available this quarter, please select a different quarter.
-26.07%
Negative 5Y equity/share growth while ENPH is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-11.49%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.73%
AR growth well above ENPH's 5.87%. Michael Burry fears inflated revenue or higher default risk in the near future.
-14.97%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
2.00%
Asset growth well under 50% of ENPH's 9.57%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
2.08%
Under 50% of ENPH's 13.01%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
0.25%
We have some new debt while ENPH reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
4.28%
R&D dropping or stable vs. ENPH's 8.65%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-4.34%
We cut SG&A while ENPH invests at 1.89%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.